Home Markets U.S. FDA panel narrowly backs Merck’s at-home COVID-19 pill

U.S. FDA panel narrowly backs Merck’s at-home COVID-19 pill

Andrew M Dec 01, 2021 comments off

Bloom Energy, Illumina, and Everpure set to join S&P 500 in quarterly rebalance